The changing face of pharma marketing:





New challenges and new opportunities

The pharmaceutical industry is undergoing a major transformation, driven by digital disruption, changing consumer expectations, and an increasingly complex regulatory environment. Traditional marketing, which was product-driven and reliant on traditional media, is now being replaced by personalized, patient-centric strategies. Today, pharma marketers must think beyond traditional advertising to build deeper, more meaningful relationships with healthcare professionals (HCPs) and patients alike.



As healthcare becomes more digitally interconnected, patients are demanding more personalized, relevant, and instantly accessible information. In fact, a recent study by Accenture found that 76% of patients prefer digital healthcare tools over traditional methods of communication with their healthcare providers.

With pharma marketers under increasing pressure to deliver more relevant, customized content, the demand for scalable content creation and Digital Asset

Management (DAM) systems has never been higher. By 2025, the global market for mHealth apps is projected to exceed \$70 billion, underlining the rise of digital solutions in healthcare.



76%

of patients prefer digital healthcare tools over traditional methods of communication


Source: Accenture



The transforming pharma marketing landscape

Pharma marketers must evolve quickly to meet the growing demands for personalized content. But this requires an agile approach to content creation, asset management, and personalized marketing. Digital transformation has become a critical enabler for pharma, allowing marketers to improve the quality, efficiency, and relevance of their campaigns.

According to a Deloitte survey, 88% of healthcare leaders believe digital technology is essential to delivering consumer value.



88%

of healthcare leaders believe digital technology is essential to delivering consumer value

Source: Deloitte




The driving forces behind consumer expectations in Pharma

The digital revolution has reshaped the healthcare landscape. With the rise of mHealth apps, telemedicine, and Al-powered tools, consumers now expect instant access to relevant health information at their fingertips. A recent report shows that 82% of patients research their health symptoms online before consulting a physician, indicating that digital health literacy is increasingly shaping consumer expectations.

Telemedicine has also played a significant role in transforming patient interactions with healthcare providers. During the COVID-19 pandemic, telemedicine services skyrocketed, as more patients turned to virtual consultations for safety and convenience. This surge has forced pharmaceutical companies to rethink their marketing strategies and develop new digital-first approaches to connect with patients and HCPs.

In parallel, artificial intelligence (AI) is transforming the pharma industry. Al tools are now used in drug discovery, diagnostics, and patient care, and they are also influencing how pharma marketers engage with patients. Al enables pharma companies to target and engage specific patient segments with tailored content, improving engagement and outcomes. For example, Al can optimize content delivery by analyzing patient behavior and predicting their needs, helping marketers create personalized experiences that resonate with their audience.




Personalization, AI, and compliance are inseparable aspects of pharma marketing



From product sellers to patient advocates

For decades, pharmaceutical marketing has been dominated by **product-centric messaging** aimed at broad audiences. Traditional marketing focused primarily on **product features** and **sales-driven campaigns**. But this approach no longer works in an era where patients expect more **personalized**, engaging, and contextually relevant information.

As the healthcare landscape evolves, pharma marketers must transition to a patient-centric approach. According to a 2019 report by McKinsey, 73% of marketers believe that personalized marketing delivers a higher return on investment (ROI) than traditional approaches. However, implementing this personalization requires overcoming significant challenges, including access to real-time patient data, content adaptation for regional markets, and ensuring content is compliant with strict healthcare regulations, GDPR and other data protection laws.



73%

of marketers believe that personalized marketing delivers a higher return on investment (ROI) than traditional approaches

Source: McKinsey



As the healthcare ecosystem becomes more digitally interconnected, pharma marketers must ensure that content not only adheres to the brand's identity but also speaks directly to the evolving needs of patients and healthcare professionals. Marketers must create content that engages consumers on a personal level while maintaining brand integrity across different channels. Digital Asset Management (DAM) and content creation platforms allow companies to scale their content efforts, enabling them to deliver on-brand content at speed across multiple channels.

Addressing privacy and compliance concerns

Data privacy and regulatory compliance are top priorities for pharma marketers, especially in light of evolving regulations like GDPR in the EU. These regulations require pharma companies to ensure the security and transparency of their data practices, especially as they collect and use patient data for personalized marketing.

Pharma marketers face the challenge of balancing **personalization** with **compliance**. As consumers grow more aware of their privacy rights, ensuring the ethical handling of consumer data is no longer optional—it's a necessity. A **recent study by Gartner** found that **63% of marketers** believe that complying with privacy regulations is a growing challenge for their marketing operations.



In the UK, non-compliance with PAGB's advertising codes or ABPI's Code of Practice for marketing prescription medicines can lead to severe consequences, including reputational damage, financial penalties, and even product recalls. According to research by The Pharmaceutical Journal, non-compliance can result in fines reaching £630,000, with some serious cases leading to even higher penalties.



Companies that violate UK pharmaceutical marketing rules face an average financial penalty of £630,000 (€765,000)

Source: The Pharmaceutical Journal

To address these compliance challenges, pharma marketers must adopt secure data handling practices, and integrate compliance-driven workflows into their content creation and distribution processes. By utilizing DAM systems, pharma companies can ensure all assets are version-controlled, audited, and securely stored, thus safeguarding patient data and ensuring compliance with GDPR. The ability to track, store, and retrieve compliant materials with ease is an essential tool for managing compliance in the digital age.




New challenges for global pharma product launches

Launching a pharmaceutical product in the modern landscape requires much more than traditional marketing tactics. It requires an agile, localized approach to meet the needs of diverse patient populations across different regions, each with its own unique regulatory environment, market dynamics, and cultural expectations.

A significant challenge for pharma marketers is producing scalable content tailored to various regional markets without compromising brand consistency. According to a survey by HubSpot, 56% of marketers report that increasing content production speed is one of their top challenges. This challenge is exacerbated by regulatory complexities across different regions, which require careful oversight and approval processes for every marketing asset.

To address this challenge, marketers must adopt solutions that enable them to **empower local teams** to create on-brand content that is both **scalable** and **regionally relevant**. **Al** and **automation tools** can help marketers speed up the content creation process while maintaining brand compliance.



56%

of marketers report that increasing content production speed is one of their top challenges.

Source: HubSpot



The role of automation and self-service

The rise of automation and self-service platforms is transforming the way pharmaceutical companies operate. According to Gartner, 70% of marketers say that automation has significantly boosted their productivity. Automation enables teams to create personalized content quickly while adhering to brand guidelines.

Self-service platforms empower local teams to create their own content using pre-approved templates, allowing them to respond more quickly to local market needs without relying on external agencies. This flexibility is crucial in an industry where time-to-market is often critical. If a pharma company is launching a new treatment for a rapidly evolving disease, being able to quickly adapt messaging to address new information or regulations can be a game-changer.





Key challenges and tangible solutions

Digital transformation and centralization of marketing tools

Pharma companies face increasing complexity managing diverse assets —clinical trial data, regulatory materials, marketing content—across various teams. Disconnected systems cause delays and compliance risks, hindering agility in responding to market trends. A centralized solution is needed.

A robust DAM system, combined with a centralized brand portal, is crucial. This unified platform ensures all assets are compliant, accessible, and up-to-date. Automated approval workflows and localized templates streamline content creation and distribution, fostering seamless collaboration across global teams.

Increased focus on compliance and regulatory risks

Navigating global regulations while maintaining speed to market poses a significant challenge. Brand consistency often conflicts with stringent compliance requirements, potentially leading to costly penalties and reputational damage. Proactive compliance solutions are needed.

A comprehensive system with enforced brand guidelines, locked templates, automated workflows, version control, and built-in regulatory checklists is essential. This ensures compliance without compromising speed or efficiency, minimizing the risk of errors and penalties.



Localization and region-specific customization


Adapting marketing materials to local regulations, languages, and cultural nuances is critical for global reach. However, creating customized content while maintaining brand consistency and managing production time effectively requires streamlined tools. Automated localization tools are needed.

A flexible asset creation and template system that supports regionspecific adaptations is vital. This empowers teams to quickly tailor marketing materials for diverse markets, ensuring consistent messaging while adhering to local regulations and brand guidelines.

Need for speed in go-to-market strategies and content scalability

The pressure to launch campaigns rapidly often results in compromises on quality, consistency, or compliance. Scaling content production without sacrificing brand integrity presents a significant challenge. Tools that enhance efficiency and speed are crucial.

A streamlined content creation platform with intuitive templates and centralized asset management is essential. Automated workflows ensure rapid approval and distribution, facilitating quick go-to-market strategies without sacrificing quality or compliance.



According to recent research, 85% of brands are creating more content year on year

Source: MarketingWeek



Increased focus on digital transformation


Digital transformation promises streamlined workflows and improved collaboration, yet many pharma companies struggle with inefficient tools and siloed marketing efforts. Integrated and user-friendly solutions are needed.

A centralized marketing operations platform that integrates various digital tools enhances collaboration across teams. Streamlined content creation and campaign execution tools significantly boost efficiency and improve overall workflow integration.

Rebranding cycles and brand refresh

Rebranding initiatives, while crucial, can be highly disruptive. Maintaining brand consistency and compliance throughout the process requires a strategic approach. Tools that support a smooth transition are crucial.

A centralized asset management system with on-brand templates facilitates a smoother rebranding process. This empowers teams to quickly adapt existing content to reflect the new brand identity, maintaining compliance and minimizing disruptions.



31%

of pharmaceutical companies rebranded after completing a merger and acquisition deal between 2014 and 2018

Source: HubSpot



Direct-to-consumer initiatives

Direct-to-consumer marketing presents new challenges in content creation, localization, and regulatory compliance. With today patients and healthcare professionals are more informed and engaged, demanding personalized content that addresses their specific needs and challenges, tools that support this are needed.

To succeed in this new environment, a flexible platform that enables the creation of compliant, on-brand content tailored to specific markets and consumer segments is essential. Automated workflows streamline the approval process, ensuring faster time-to-market for direct-to-consumer campaigns.

Refreshing employer branding to attract talent

Attracting top talent requires a strong employer brand that resonates with today's job seekers. Creating engaging, modern recruitment materials while maintaining brand consistency necessitates effective tools.

A system that empowers HR and recruitment teams to easily adapt employer branding content using pre-approved templates is essential. This allows for creating visually appealing, on-brand recruitment materials that connect with today's talent pool.



Conclusion

Pharma marketing has entered a new era of digital transformation. By leveraging agile content creation tools, DAM systems, and automation technologies, pharma marketers can meet the evolving needs of patients and healthcare professionals while maintaining brand integrity and compliance. As AI, telemedicine, and mHealth apps continue to disrupt the industry, pharma marketers must stay ahead of these trends and adapt their strategies to deliver relevant, personalized, and timely content. The future of pharma marketing lies in embracing these innovations and ensuring that every patient interaction is meaningful, personalized, and aligned with brand values.




How Papirfly makes the difference for pharma marketing teams

Papirfly's suite of tools for content creation and Digital Asset

Management (DAM) ensures that marketing teams can consistently create
and deliver content that is not only on-brand but also aligned with the
specific needs of their audiences. With Papirfly, pharma companies can:

- Empower teams to create high-quality, on-brand content quickly and efficiently
- Ensure brand consistency across diverse markets and campaigns
- Scale content creation to meet the demands of growing marketing teams and expanding global markets
- Easily manage digital assets, providing one central hub for content that reflects the brand's identity

The future of pharma marketing is here. With **Papirfly**, marketing teams can embrace the digital revolution and meet the evolving expectations of their customers—all while maintaining brand integrity and governance.





Ready to embrace the future of pharma marketing?

Discover how Papirfly's Digital Asset

Management (DAM) and on-brand content

creation tools can help you drive personalized,

compliant marketing at scale



- www.papirfly.com
- (in) /company/papirfly
- (f) /papirflyglobal
- ▶ /@papirfly